NTP42 is a selective thromboxane-prostanoid (TP) receptor antagonist primarily used in medical research for its therapeutic potential in fibrotic and inflammatory diseases, with a focus on idiopathic pulmonary fibrosis (IPF) and other respiratory conditions such as COPD and asthma. It inhibits TP receptor-mediated signaling, which reduces inflammation, fibrosis, and bronchoconstriction in the airways. Additionally, its ability to block thromboxane-induced platelet aggregation makes it promising for cardiovascular applications, including thrombosis, hypertension, and vascular remodeling. NTP42 also exhibits anti-inflammatory effects beneficial for chronic inflammatory disorders and is under investigation for modulating cellular responses in cancer therapy, potentially targeting tumor growth and metastasis. As a niche research compound, it serves as a tool to study TP receptor pathways, though further clinical trials are needed to confirm its efficacy and safety.